Pharmacoepidemiology of Anemia in Kidney Transplant Recipients

Journal of the American Society of Nephrology

Volumn 15, Issue 5, 2004, Pages 1347-1352

  Winkelmayer, Wolfgang C ^a   Kewalramani, Reshma ^a   Rutstein, Mark ^a   Gabardi, Steven ^a   Vonvisger, Tania ^a   Chandraker, Anil ^a,b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN 2 RECEPTOR ANTAGONIST; AZATHIOPRINE; CAPTOPRIL; CORTICOSTEROID; CREATININE; CYCLOSPORIN A; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; ERYTHROPOIETIN; FOSINOPRIL; IMMUNOSUPPRESSIVE AGENT; IRBESARTAN; LISINOPRIL; LOSARTAN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; QUINAPRIL; RAMIPRIL; RAPAMYCIN; TACROLIMUS; VALSARTAN;

ADULT; ANEMIA; ARTICLE; CONTROLLED STUDY; COVARIANCE; DISEASE ASSOCIATION; DOSE RESPONSE; FEMALE; GENDER; GRAFT REJECTION; HEMATOCRIT; HUMAN; INFORMATION PROCESSING; KIDNEY FUNCTION; KIDNEY GRAFT; KIDNEY TRANSPLANTATION; LINEAR REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; MULTIVARIATE ANALYSIS; OUTPATIENT DEPARTMENT; PHARMACOEPIDEMIOLOGY; POSTOPERATIVE PERIOD; PREDICTION; PREVALENCE; PRIORITY JOURNAL; RECIPIENT; RETROSPECTIVE STUDY;

EID: 1942506491     PISSN: 10466673     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ASN.0000125551.59739.2E     Document Type: Article

References (24)

1. Eschbach JW, Adamson JW: Anemia of end-stage renal disease (ESRD). Kidney Int 28: 1-5, 1985
2. Wizemann V, Schafer R, Kramer W: Follow-up of cardiac changes induced by anemia compensation in normotensive hemodialysis patients with left-ventricular hypertrophy. Nephron 64: 202-206, 1993
3. Harnett JD, Foley RN, Kent GM, Barre PE, Murray D, Parfrey PS: Congestive heart failure in dialysis patients: Prevalence, incidence, prognosis and risk factors. Kidney Int 47: 884-890, 1995
4. Mann JFE: What are the short-term and long-term consequences of anemia in CRF patients? Nephrol Dial Transplant 14[Suppl 2]: S29-S36, 1999.
5. Silberberg JS, Rahal DP, Patton R, Sniderman AD: Role of anemia in the pathogenesis of left ventricular hypertrophy in end-stage renal disease. Am J Cardiol 64: 222-224, 1989
6. Wizemann V, Kaufmann J, Kramer W: Effect of erythropoietin on ischemia tolerance in anemic hemodialysis patients with confirmed coronary artery disease. Nephron 62: 161-165, 1992
7. Cannella G, La Canna G, Sandrini M, Gaggiotti M, Nordio G, Movilli E, Maiorca R: Renormalization of high cardiac output and of left ventricular size following long-term recombinant human erythropoietin treatment of anemic dialyzed uremic patients. Clin Nephrol 34: 272-278, 1990
8. Macdougall IC, Lewis NP, Saunders MJ, Cochlin DL, Davies ME, Hutton RD, Fox KAA, Coles GA, Williams JD: Long-term cardiorespiratory effects of amelioration of renal anaemia by erythropoietin. Lancet 335: 489-493, 1990
9. Pascual J, Teruel JL, Moya JL, Liano F, Jimenez-Mena M, Ortuno J: Regression of left ventricular hypertrophy after partial correction of anemia with erythropoietin in patients on hemodialysis: A prospective study. Clin Nephrol 35: 280-287, 1991
10. Mocks J, Franke W, Ehmer B, Scigalla P, Quarder O: Analysis of safety database for long-term epoetin-beta treatment. A meta-analysis covering 3697 patients. In: Pathogenetic and Therapeutic Aspects of Chronic Renal Failure. Koch KM, Stein G, eds, New York, Marcel Dekker, 1997, pp 163-179
11. Consensus Development Conference Panel: Morbidity and mortality of renal dialysis: An NIH consensus conference statement. Ann Intern Med 121: 62-70, 1994
12. Grutzmacher P, Scheuermann E, Low I, Bergmann M, Rauber K, Baum R, Heuser J, Schoeppe W: Correction of renal anaemia by recombinant human erythropoietin: Effects on myocardial function. Contrib Nephrol 66: 176-184, 1988
13. Ma JZ, Ebben J, Xia H, Collins AJ: Hematocrit level and associated mortality in hemodialysis patients. J Am Soc Nephrol 10: 610-619, 1999
14. Silberberg J, Racine N, Barre P, Sniderman AD: Regression of left ventricular hypertrophy in dialysis patients following correction of anemia with recombinant human erythropoietin. Can J Cardiol 1626: 1-4, 1990
15. Paganini EP: In search of an optimal hematocrit level in dialysis patients: Rehabilitation and quality-of-life implications. Am J Kidney Dis 24: S10-S16, 1994
16. Xia H, Ebben J, Ma JZ, Collins AJ: Hematocrit levels and hospitalization risks in hemodialysis patients. J Am Soc Nephrol 10: 1309-1316, 1999
17. Saito S, Fujiwara T, Sakagami K, Matsuno T, Tanaka N: Anemia following renal transplantation. Transplant Proc 30: 3025-3026, 1998
18. Lorenz M, Kletzmayr J, Perschl A, Furrer A, Hörl WH, Sunder-Plassmann G: Anemia and iron deficiencies among long-term renal transplant recipients. J Am Soc Nephrol 13: 794-797, 2002
19. Yorgin PD, Scandling JD, Belson A, Sanchez J, Alexander SR, Andreoni KA: Late post-transplant anemia in adult renal transplant recipients. An under-recognized problem? Am J Transplant 2: 429-435, 2002
20. Vanrenterghem Y, Ponticelli C, Morales JM, Abramowitz D, Baboolal K, Eklund B, Kliem V, Legrendre C, Sarmiento ALM, Vincenti F: Prevalence and management of anemia in renal transplant recipients: a European survey. Am J Transplant 3: 835-845, 2003
21. Mix TCH, Kazmi W, Khan S, Ruthazer R, Rohrer R, Pereira BJG, Kausz AT: Anemia: A continuing problem following kidney transplantation. Am J Transplant 3: 1426-1433, 2003
22. Lewis EJ, Hunsicker LG, Bain RP, Rohde ED: The effect of angiotensin-converting enzyme inhibition on diabetic nephropathy. N Engl J Med 329: 1456-1462, 1993
23. Giatras I, Lau J, Levey A: Effect of angiotensin-converting enzyme inhibitors on the progression of non-diabetic renal disease: a meta-analysis of randomized trials. Ann Intern Med 127: 337-345, 1997
24. Stigant CE, Cohen J, Vivera M, Zaltzman JS: ACE inhibitors and angiotensin II antagonists in renal transplantation: an analysis of safety and efficacy. Am J Kidney Dis 35: 58-63, 2000